dengue vaccines


Summary: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.

Top Publications

  1. Whitehead S, Durbin A, Pierce K, Elwood D, McElvany B, Fraser E, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017;11:e0005584 pubmed publisher
    ..As candidate dengue vaccines become available in endemic settings and for individuals who have received other flavivirus vaccines, it is ..
  2. Normile D. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science. 2013;342:415 pubmed publisher
  3. Pang T. SAGE committee advice on dengue vaccine. Lancet Infect Dis. 2016;16:880-2 pubmed publisher
  4. Hertz T, Beatty P, MacMillen Z, Killingbeck S, Wang C, Harris E. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. J Immunol. 2017;198:4025-4035 pubmed publisher
    ..Overall, we identified a small number of immunodominant regions, which were in functionally important locations on the DENV NS1 protein and are potential correlates of protection. ..
  5. Kularatne S. Dengue fever. BMJ. 2015;351:h4661 pubmed publisher
  6. Shim E. Cost-Effectiveness of Dengue Vaccination Programs in Brazil. Am J Trop Med Hyg. 2017;96:1227-1234 pubmed publisher
    ..Our results show that dengue vaccination would be cost-effective in Brazil even with a relatively low vaccine efficacy in seronegative individuals. ..
  7. Beatty M, Boni M, Brown S, Buathong R, Burke D, Coudeville L, et al. Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl Trop Dis. 2012;6:e1450 pubmed publisher
  8. Simmons C. A Candidate Dengue Vaccine Walks a Tightrope. N Engl J Med. 2015;373:1263-4 pubmed publisher
  9. Jin X, Lee M, Shu J. Dengue fever in China: an emerging problem demands attention. Emerg Microbes Infect. 2015;4:e3 pubmed publisher

More Information


  1. Mahalingam S, Herring B, Halstead S. Call to action for dengue vaccine failure. Emerg Infect Dis. 2013;19:1335-7 pubmed publisher
  2. Rodriguez Barraquer I, Mier y Teran Romero L, Burke D, Cummings D. Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis. 2013;7:e2126 pubmed publisher
  3. . Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations. Wkly Epidemiol Rec. 2016;91:266-84 pubmed
  4. Wilder Smith A. Dengue vaccines: dawning at last?. Lancet. 2014;384:1327-9 pubmed publisher
  5. Valdes I, Marcos E, Suzarte E, Pérez Y, Brown E, Lazo L, et al. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. Arch Virol. 2017;162:2247-2256 pubmed publisher
    ..This study provides new information about the functionality of Tetra DIIIC as a vaccine candidate and also supports the crucial role of cell-mediated immunity in protection against dengue virus. ..
  6. Halstead S. Dengue vaccine development: a 75% solution?. Lancet. 2012;380:1535-6 pubmed publisher
  7. Schmidt A, Lin L, Martinez L, Ruck R, Eckels K, Collard A, et al. Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States. Am J Trop Med Hyg. 2017;96:1325-1337 pubmed publisher
    ..In the nine subjects where boosting was evaluated, a strong anamnestic response was observed. These results support continuation of the clinical development of this dengue vaccine candidate ( NCT01666652). ..
  8. Barba Spaeth G, Dejnirattisai W, Rouvinski A, Vaney M, Medits I, Sharma A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536:48-53 pubmed publisher
  9. Thomas S. The necessity and quandaries of dengue vaccine development. J Infect Dis. 2011;203:299-303 pubmed publisher
  10. Rodriguez Barraquer I, Mier y Teran Romero L, Ferguson N, Burke D, Cummings D. Differential efficacy of dengue vaccine by immune status. Lancet. 2015;385:1726 pubmed publisher
  11. Zorlu G, Fleck F. Dengue vaccine roll-out: getting ahead of the game. Bull World Health Organ. 2011;89:476-7 pubmed publisher
  12. Edelman R. Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Rev Vaccines. 2011;10:133-6 pubmed publisher
  13. . Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015¹. Safety of CYD-TDV dengue vaccine. Wkly Epidemiol Rec. 2015;90:421-3 pubmed
  14. Russell P, Halstead S. Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines. PLoS Negl Trop Dis. 2016;10:e0004854 pubmed publisher
  15. World Health Organization -. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017;35:1200-1201 pubmed publisher
    ..Recommendations on the use of this dengue vaccine were discussed by SAGE in April 2016; evidence presented at that SAGE meeting can be accessed at:
  16. Bischof G, Magnani D, Ricciardi M, Shin Y, Domingues A, Bailey V, et al. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys. J Virol. 2017;91: pubmed publisher
    ..These findings underscore the potential utility of recombinant herpesviruses as vaccine vectors. ..
  17. Halstead S. Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infect Dis. 2017;17:e378-e382 pubmed publisher
    ..T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines. ..
  18. Simmons C, Farrar J. Changing patterns of dengue epidemiology and implications for clinical management and vaccines. PLoS Med. 2009;6:e1000129 pubmed publisher
  19. Magnani D, Silveira C, Ricciardi M, Gonzalez Nieto L, Pedreño Lopez N, Bailey V, et al. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine. J Virol. 2017;91: pubmed publisher
    ..Here, we describe the isolation of potent (Neut50 < 0.1 ?g/ml) nAbs from a DENV-seropositive volunteer immunized with the tetravalent vaccine Butantan-DV, which is currently in phase III trials. ..
  20. Aguiar M, Stollenwerk N, Halstead S. The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016;16:882-3 pubmed publisher
  21. Muthusamy K, Gopinath K, Nandhini D. Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination. Indian J Med Res. 2016;144:587-591 pubmed publisher
    ..Therefore, the immunodominant antigenic region (VDRGWGNGCGLFGKG) and 15 potential epitopes may be considered for use in dengue vaccines.
  22. Thomas S. Preventing dengue--is the possibility now a reality?. N Engl J Med. 2015;372:172-3 pubmed publisher
  23. Swaminathan S, Khanna N, Herring B, Mahalingam S. Dengue vaccine efficacy trial: does interference cause failure?. Lancet Infect Dis. 2013;13:191-2 pubmed publisher
  24. Fitzpatrick C, Haines A, Bangert M, Farlow A, Hemingway J, Velayudhan R. An economic evaluation of vector control in the age of a dengue vaccine. PLoS Negl Trop Dis. 2017;11:e0005785 pubmed publisher
    ..High-burden endemic countries should proceed to map populations to be covered by sustained vector control. ..